Comparison between Topical Beta-Sitosterol and Topical Hirudin in Management of Facial Burns

Document Type : Original Article

Authors

The Department of Plastic Surgery, Faculty of Medicine, Suez Canal University

Abstract

Background: Facial burns are challenging, as the aesthetic
outcome is as important as the functional. Topical interventions
are currently the cornerstone of treatment of facial burns.
Although there is no gold standard agent for the treatment of
facial burns, beta-sitosterol is the most commonly used as first
line agent.
Recombinant hirudin is an agent derived from medicinal
leech and it has anti-thrombotic action, which is thought to
have effect on facial burns healing.
Objective: The objective of this study is to compare the effect
of beta-sitosterol and hirudin in the management of facial
burns regarding the pain, edema, healing time, and aesthetic
outcome.
Patients and Methods: A concurrent self-control open label
clinical trial was conducted on fifteen patients attending the
burn unit at Suez Canal University Hospital with facial burns.
Visual Analogue Scale for pain to time, edema, hospitalization
time, healing time, scarring by the patient and observer scar
assessment scale (POSAS) and final aesthetic outcome.
Expected Outcome: In patients with facial burns, the use
of topical hirudin will reduce pain and edema; enhance faster
healing and less hospitalization time, less scarring and better
final aesthetic outcome.
Conclusion: Topical hirudin use in facial burns is a safe and
effective option as it showed statistically significant results regarding
wound healing and final scar quality outcome that was
better than topical beta-sitosterols. Although its effects regarding
pain and edema showed no statically significant difference in
comparison to topical beta-sitosterols, it should be considered as
an effective safe option in the treatment of facial burns.

Keywords

Main Subjects

References

Ang E.S., Lee S.T., Gan C.S., et al.: The role of alternative
therapy in the management of partial thickness burns of
the face-experience with the use of moist exposed burn
ointment (MEBO) compared with silver sulphadiazine.
Ann. Acad. Med. Singap, 29 (1): 7-10, 2000.
2- Azizkhan R.G., Azizkhan J.C., Zetter B.R. and Folkman
J.: Mast cell heparin stimulates migration of capillary endothelial
cells in vitro. J. Exp. Med., 152 (4): 931-944,
1980.
3- Buderer N.M.: Statistical methodology: I. Incorporating
the prevalence of disease into the sample size calculation
for sensitivity and specificity. Acad. Emerg. Med., 3 (9):
895-900, 1996.
4- Chae J.K., Kim J.H., Kim E.J. and Park K.: Values of a Patient
and Observer Scar Assessment Scale to Evaluate the
Facial Skin Graft Scar. Ann. Dermatol., 28 (5): 615-623,
2016.
5- Clark C., Ledrick D. and Moore A.: Facial Burns. In: Stat-
Pearls. Treasure Island (FL): StatPearls Publishing, July 8,
2021.
6- Demling R.H. and Pomposelli J.J.: In: Surgical Infections.
Meakins J.L., editor. New York: Scientific American Medicine,
369-373, 1994.
7- Demling R.H., Wong C., Jin L.J., Hechtman H., Lalonde
C. and West K.: Early lung dysfunction after major burns:
Role of edema and vasoactive mediators. J. Trauma, 25
(10): 959-966, 1985.
8- El-Hadidy M.R., El-Hadidy A.R., Bhaa A., Asker S.A.
and Mazroa S.A.: Role of epidermal stem cells in repair
of partial-thickness burn injury after using Moist Exposed
Burn Ointment (MEBO(®)) histological and immunohistochemical
study. Tissue Cell, 46 (2): 144-151, 2014.
9- Fawzy Ahmed Hamza, Ahmed Abu-Elsoud Salim and
Hossam Nasr Rizk: “Evaluation of the Effect of Topical
Heparin on the Treatment of Facial Burn”. Al-Azhar International
Medical Journal, 1 (2): 198-202, 2020.
10- Gojowy D., Kauke M., Ohmann T., Homann H.H. and
Mannil L.: Early and late-recorded predictors of health-related
quality of life of burn patients on long-term follow-
up. Burns, 45 (6): 1300-1310, 2019.
11- Griffin J.E. and Johnson D.L.: Management of the maxillofacial
burn patient: Current therapy. J. Oral Maxillofacial
Surg., 63 (2): 247-252, 2005.
12- Gupta A., Gupta P. and Verghese T.: Role of topical heparin
in the management of burns. Experience in a district
government hospital of Karnataka in South India, 2 (3):
111-112, 2015.
13- Hoogewerf C.J., Hop M.J., Nieuwenhuis M.K., Oen I.M.,
Middelkoop E. and Van Baar M.E.: Topical treatment
for facial burns. Cochrane Database Syst. Rev., 7 (7):
CD008058, 2020. Published 2020 Jul 29.
14- ISBI Practice Guidelines Committee: Steering Subcommittee;
Advisory Subcommittee. ISBI Practice Guidelines
for Burn Care. Burns, 42 (5): 953-1021, 2016.
15- ISBI Practice Guidelines Committee: Advisory Subcommittee;
Steering Subcommittee. ISBI Practice Guidelines
for Burn Care, Part 2. Burns, 44 (7): 1617-1706, 2018.
16- Draaijers L.J., Tempelman F.R., Botman Y.A., Tuinebreijer
W.E., Middelkoop E., Kreis R.W., et al.: The patient
and observer scar assessment scale: A reliable and feasible
for scar evaluation. Plast Reconstr Surg., 113 (7): 1960-
1967, 2004.
17- Maciag T., Mehlman T., Friesel R. and Schreiber A.B.:
Heparin binds endothelial cell growth factor, the principal
endothelial cell mitogen in bovine brain. Science, 225
(4665): 932-935, 1984.
18- Manzoor S., Khan F.A., Muhammad S., et al.: Comparative
study of conventional and topical heparin treatment in
second degree burn patients for burn analgesia and wound
healing. Burns, 45 (2): 379-386, 2019.
19- Markwardt F.: The development of hirudin as an antithrombotic
drug. Thromb. Res., 74: 1-23, 1994.
20- Masoud M., Wani A.H. and Darzi M.A.: Topical heparin
versus conventional treatment in acute burns: A comparative
study. Indian J. Burns, 22: 43-50, 2014.
21- Mertens D.M., Jenkins M.E. and Warden G.D.: Outpatient
burn management. Nurs. Clin. North. Am., 32 (2): 343-
364, 1997.
22- Moher D., Schulz K.F. and Altman D.G.: The CONSORT
Statement. Revised recommendations for improving the
quality of reports of parallel-group randomized trials. Lancet,
357 (9263): 1191-1194, 2001.
23- Nowak G.: Pharmacology of recombinant hirudin. Semin.
Thromb. Hemost., 28: 415-423, 2002.
24- Palmieri T.L., Przkora R., Meyer W.J. and Carrougher
G.J.: Measuring burn injury outcomes. Surg. Clin. North.
Am.,94 (4): 909-916, 2014.
25- Saliba M.J. Jr., Dempsey W.C. and Kruggel J.L.: Large
burns in humans. Treatment with heparin. JAMA, 225 (3):
261-269, 1973.
26- Saliba Jr., M.J.: “Heparin In Burns Protocol.” Internet
website: http://www. salibaburnsinstitute. org and ProEgypt,
J. Plast. Reconstr. Surg., January 2024 15
ceedings, Heparin Effects In Burns International Symposium,
2000.
27- Saliba M.J. Jr. and Saliba R.J.: Heparin in burns. Dose
related and dose dependent effects. Thromb Diath Haemorrh.,
33 (1): 113-123, 1975.
28- Teles G.G. do A. and Bastos J.A.: Treatment of superficial
Second- degree burn of face and neck with topical heparin.
A comparative, prospective and randomized study. Revista
Brasileira de Cirurgia Plástica. SciELO Brasil, 27: 383-
386, 2012.
29- Venkatachalapathy T.S.: A comparative Study of Pediatric
Thermal Burns Treated with Topical Heparin and Without
Heparin. Indian Journal of Surgery, 76 (4): 282-287, 2014.
30- Venakatachalapathy T.S., Mohan Kumar S. and Saliba
M.J.: A comparative study of burns treated with topical
heparin and without heparin. Annals of Burns and Fire
Disasters, 20 (4): 189-198, 2007.
31- von Arx T., Tamura K., Yukiya O. and Lozanoff S.: The
Face. A Vascular Perspective. A literature review. Swiss
Dent J., 128 (5): 382-392,

Files

Share

How to cite

Statistics